Know Labs has put forward additional proof-of-concept data from its needle-free blood sugar monitor, designed to continuously scan the blood through a person’s skin.

Pfizer inadvertently gave a leg up to two obesity biotechs yesterday with the announcement that an extended-release formulation of oral med danuglipron will be advanced into dose optimization studies.

The Biomedical Advanced Research and Development Authority (BARDA) has awarded a $749,999 contract to Cambridge, Massachusetts-based Tiba Biotech to develop a new RNAi-based therapeutics, starting with a treatment for swine flu.

BD is seeing a shortage of its blood culture vials used to support a wide array of infectious disease diagnostics, and the FDA is urging healthcare providers to ration their current supplies and preserve them for patients at the highest risk.

Young adult mice with a genetic form of progressive deafness can hear again after being treated with an experimental CRISPR gene therapy that its creators hope to eventually use in humans.

Pfizer has dragged the oral GLP-1 candidate danuglipron back from the brink. Months after dropping one version of the asset, the Big Pharma has vowed to advance a once-daily, modified-release formulation on the strength of “encouraging pharmacokinetic data.”

Clinical trial geography has undergone a major shift in the past five years, with China’s share of the world’s trials jumping nearly 60% amid declines in Europe, according to a report released July 10 by the IQVIA Institute, the research arm of pharma data and testing solutions provider IQVIA.

Despite letting go of Grail last month, Illumina isn’t shying away from M&A. The DNA sequencing giant has now acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research.

Kazia Therapeutics has found a way to try to salvage a win from a failed late-phase brain cancer trial. By removing part of the control arm, the biotech has emerged with survival data it will share with the FDA to see whether a path to accelerated approval has opened up.

The FDA has elevated a recall of Inspire Medical’s nerve-stimulating implant for the treatment of obstructive sleep apnea.